Compare AbbVie Inc (ABBV) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Riot Platforms Inc — how do they compare? AbbVie Inc trades at $253.6 (market cap $449.91B), while Riot Platforms Inc trades at $20.67 (market cap $8.01B). The key difference: AbbVie Inc is far larger — about 56.2× Riot Platforms Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| ABBV | RIOT | |
|---|---|---|
Market Cap | $449.91B | $8.01B |
Sector | Health | Technology |
52-Week High | $261.07 | $28.67 |
52-Week Low | $184.85 | $11.03 |
Enterprise Value | $513.38B | $8.68B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
RIOT trades at $22.87, up 3.44% today, but technical indicators signal a bearish trend with resistance at $24. The company reported a net loss of $663.18 million in 2025 with negative cash flow from operations, though revenue reached $647.44 million. Recent news highlights volatility tied to Bitcoin price swings and a strategic pivot toward high-performance computing data centers, including a partnership with Terrestrial Energy for nuclear-powered facilities.
Wall Street analysts remain overwhelmingly bullish with a 94% buy rating and $27.83 consensus price target, but high valuation multiples and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI data center strategy amid competitive and regulatory pressures in the energy-intensive mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
